Home Metliptin 50/850mg Tablet
Metliptin 50/850mg Tablet – Available in Pakistan
Nebivol 5mg Tablets Pakistan — Nebivolol Standard Maintenance Dose for Hypertension – View Product Detail
Metliptin 50/850mg Tablet – Available in Pakistan
Nebivol 5mg Tablets Pakistan — Nebivolol Standard Maintenance Dose for Hypertension – View Product Detail

Metliptin 50/850mg Tablet

Metliptin 50/850mg Tablet combines Vildagliptin 50mg and Metformin HCl 850mg for type 2 diabetes control. This intermediate-dose formulation is suitable for patients who require more glycaemic control than the 500mg strength but are not yet on maximum-dose Metformin. Prescription medicine — use only under medical supervision.

Sale price Rs. 844

Pay in 3 Installments of

Rs.

323

Availability: In stock SKU: DRM-9IF4
Tags: anti-diabetic tablet Pakistan blood sugar control diabetes combination therapy diabetes medicine Pakistan DPP-4 inhibitor glycemic control metformin 850mg Metliptin 2 diabetes vildagliptin 50mg vildagliptin metformin
Metliptin 50/850mg Tablet – Available in Pakistan

Metliptin 50/850mg Tablet

Rs. 844

Metliptin 50/850mg Tablet — Vildagliptin + Metformin for Type 2 Diabetes

Metliptin 50/850mg Tablet is a combination of Vildagliptin 50mg and Metformin HCl 850mg, used in the management of type 2 diabetes mellitus. The 850mg metformin strength offers an intermediate dose suitable for patients who require stronger glycaemic control than the 500mg combination but without the maximum 1000mg dose.

Vildagliptin (DPP-4 inhibitor) enhances the body's natural incretin response, stimulating insulin release and suppressing glucagon after meals. Metformin reduces liver glucose production and improves cellular insulin sensitivity. Together, they deliver sustained blood sugar reduction with a low risk of hypoglycaemia.

Indications

  • Type 2 diabetes mellitus in adults
  • Patients requiring step-up from 500mg to 850mg metformin combination
  • Adjunct to diet and exercise for glycaemic control

Important Warnings

  • Prescription medicine — consult your doctor before starting
  • Not for type 1 diabetes or acute metabolic acidosis
  • Withhold before contrast imaging procedures
  • Regular monitoring of HbA1c and renal function recommended

Browse our Anti-Diabetic medicines or General Medicines for more diabetes management options in Pakistan.

Order in Pakistan

Buy Metliptin 50/850mg Tablet at Derma.pk with nationwide COD delivery. WhatsApp: +92-320-5999650.

Usage & Benefits

Intermediate-strength combination for effective type 2 diabetes management
Vildagliptin (DPP-4 inhibitor) boosts insulin secretion and reduces glucagon
Metformin 850mg reduces liver glucose output and improves insulin sensitivity
Low risk of hypoglycaemia as a dual combination
Helpful step-up option between 500mg and 1000mg Metformin strengths

How To Use

Take one tablet twice daily with meals (morning and evening), or as prescribed.
Swallow whole with water — do not crush or chew the tablet.
Take with food to minimise gastrointestinal discomfort.
Maintain a balanced diet and regular exercise for optimal blood sugar control.
Regularly monitor blood glucose and attend follow-up appointments.
Store below 30°C in a dry place away from direct sunlight.

FAQs

What is Metliptin 50/850mg used for?

It is used to manage type 2 diabetes in adults when diet, exercise, or single-agent therapy does not achieve adequate blood sugar control.

How is 850mg different from 500mg and 1000mg?

850mg is an intermediate dose providing more glycaemic effect than 500mg but with a lower total Metformin load than 1000mg, often used as a step-up dose.

Is Metliptin 50/850mg safe for long-term use?

Yes, it is commonly used as long-term maintenance therapy for type 2 diabetes under regular medical review.

What should I avoid while taking Metliptin?

Excessive alcohol, contrast dye procedures (temporarily withheld), and skipping meals which can affect glucose levels.

When will I see results in my blood sugar levels?

Most patients see improvement in fasting glucose within days; HbA1c improvement is assessed at the 3-month mark.